Literature DB >> 7159463

Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin.

G Laurent, M B Carlier, B Rollman, F Van Hoof, P Tulkens.   

Abstract

Gentamicin, a widely used aminoglycoside antibiotic, is concentrated in lysosomes of proximal tubular cells of the kidney, and induces therein an accumulation of myelin-like material. We show that treatment of rats with Gentamicin (10 mg/kg, 7 days) induces a loss of activity of lysosomal sphingomyelinase and phospholipase A1, associated with an increase in the amount of total lipid phosphorus in the kidney cortex. In vitro, Gentamicin is shown by gel permeation to bind to phospholipid bilayers (liposomes) under conditions which mimic the lysosomal environment (acid pH and presence of phosphatidylinositol). The reversal of this binding by an increase in the ionic strength (less than 0.04) suggests electrostatic interaction between the hydrophilic, polycationic aminoglycoside and the negatively charged phospholipids. Binding of Gentamicin impairs the hydrolysis of phosphatidylcholine present in the bilayer, by lysosomal phospholipases A1 and A2 from the liver or kidney. We also show that lysosomal sphingomyelinase is readily and irreversibly inactivated by liposomes in the absence of detergent. The lysosomal phospholipidosis induced by Gentamicin in the kidney, as in cultured cells [Aubert-Tulkens et al., Lab. Invest. 40, 481 (1979)] appears therefore to be a direct consequence of the lysosomotropic character of this drug and its ability to inhibit therein phospholipid breakdown. Amikacin, a semi-synthetic aminoglycoside, binds more loosely to phospholipid bilayers, induces less inhibition of phospholipases in vitro and is less taken up by tubular cells in vivo. Accordingly, Amikacin does not provoke significant lysosomal phospholipidosis or loss of sphingomyelinase and phospholipase A1 activities in vivo at the doses and time investigated (0-40 mg/kg, 7 days). Inasmuch as Amikacin is reported to be less toxic to the kidney, we suggest that lysosomal alterations are an early and significant step in aminoglycoside-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159463     DOI: 10.1016/0006-2952(82)90303-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  46 in total

1.  Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration.

Authors:  M LeBrun; L Grenier; P Gourde; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice.

Authors:  M C Lecaroz; M J Blanco-Prieto; M A Campanero; H Salman; C Gamazo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 3.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Light- and electron-microscopic analysis of the kidney in newborn rats exposed to gentamicin in utero.

Authors:  T Gilbert; B Nabarra; C Merlet-Bénichou
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

5.  Infective endocarditis due to Streptococcus dysgalactiae: clinical presentation and microbiological features.

Authors:  Anna Bläckberg; Bo Nilson; Volkan Özenci; Lars Olaison; Magnus Rasmussen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-08       Impact factor: 3.267

6.  Renoprotective effect of red ginseng in gentamicin-induced acute kidney injury.

Authors:  Hyun-Soo Shin; Mina Yu; Mijin Kim; Hack Sun Choi; Duk-Hee Kang
Journal:  Lab Invest       Date:  2014-08-11       Impact factor: 5.662

Review 7.  Therapeutics based on stop codon readthrough.

Authors:  Kim M Keeling; Xiaojiao Xue; Gwen Gunn; David M Bedwell
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-18       Impact factor: 8.929

8.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin.

Authors:  M Couture; M Simard; P Gourde; C Lessard; K Gurnani; L Lin; D Carrier; M G Bergeron; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Influence of endotoxin on the intracortical accumulation kinetics of gentamicin in rats.

Authors:  D Tardif; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.